

## DAFTAR PUSTAKA

- Ando, K., Heymann, M.F., Stresing, V., Mori, K., Rédini, F. and Heymann, D., 2013. Current therapeutic strategies and novel approaches in osteosarcoma. *Cancers*, 5(2), pp.591-616, DOI: 10.3390/cancers5020591
- Bacci, G., Bertoni, F., Longhi, A., Ferrari, S., Forni, C., Biagini, R., Bacchini, P., Donati, D., Manfrini, M., Bernini, G. and Lari, S., 2003. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity: histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. *Cancer*, 97(12), pp.3068-3075, DOI: 10.1002/cncr.11456
- Bacci, G., Mercuri, M., Longhi, A., Ferrari, S., Bertoni, F., Versari, M. and Picci, P., 2005. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. *European journal of cancer*, 41(14), pp.2079-2085, DOI: 10.1016/j.ejca.2005.03.036
- Bajpai, J., Chandrasekharan, A., Simha, V., Mandal, T., Shah, K., Hingmare, S., Rangarajan, B., Shetty, N., Vora, T., Ghosh, J., Rekhi, B., Banavali, S. and Gupta, S., 2019. Osteosarcoma journey over two decades in India: Small steps, big changes. *Pediatric blood & cancer*, 66(9), e27877, DOI: 10.1002/pbc.27877
- Bajpai, J., Chandrasekharan, A., Talreja, V., Simha, V., Chandrakanth, M.V., Rekhi, B., Khurana, S., Khan, A., Vora, T., Ghosh, J. and Banavali, S.D., 2017. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dose methotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'. *European Journal of Cancer*, 85, pp.49-58, DOI: 10.1016/j.ejca.2017.08.013
- Bielack, S.S., Hecker-Nolting, S., Blattmann, C. and Kager, L., 2016. Advances in the management of osteosarcoma. *F1000Research*, 5, DOI: 10.12688/f1000research.9465.1
- Bielack, S.S., Kempf-Bielack, B., Delling, G., Exner, G.U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W. and Zoubek, A., 2002. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. *Journal of clinical oncology*, 20(3), pp.776-790, DOI: 10.1200/JCO.2002.20.3.776
- Bishop, M.W., Chang, Y.C., Krailo, M.D., Meyers, P.A., Provisor, A.J., Schwartz, C.L., Marina, N.M., Teot, L.A., Gebhardt, M.C., Gorlick, R. and

- Janeway, K.A., 2016. Assessing the prognostic significance of histologic response in osteosarcoma: a comparison of outcomes on CCG-782 and INT0133—a report from the Children's Oncology Group Bone Tumor Committee. *Pediatric blood & cancer*, 63(10), pp.1737-1743, DOI: 10.1002/psc.26034
- Carrle, D. and Bielack, S.S., 2006. Current strategies of chemotherapy in osteosarcoma. *International orthopaedics*, 30, pp.445-451, DOI: 10.1007/s00264-006-0192-x
- Choeprasert, W., Natesirinilkul, R., Charoenkwan, P. and Sittipreechacharn, S., 2013. Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand. *Asian Pacific Journal of Cancer Prevention*, 14(2), pp.1101-1106, DOI: 10.7314/apjcp.2013.14.2.1101
- Davis, A.M., Bell, R.S. and Goodwin, P.J., 1994. Prognostic factors in osteosarcoma: a critical review. *Journal of Clinical Oncology*, 12(2), pp.423-431, DOI: 10.1200/JCO.1994.12.2.423
- Daw, N.C., Neel, M.D., Rao, B.N., Billups, C.A., Wu, J., Jenkins, J.J., Quintana, J., Luchtman-Jones, L., Villarroel, M. and Santana, V.M., 2011. Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. *Cancer*, 117(12), pp.2770-2778, DOI: 10.1002/cncr.25715
- Ferdiansyah Mahyudin, N.I.D.N., Edward, M., Basuki, M.H., Bari, Y.A. and Suwandani, Y., 2018. Osteosarcoma has not become attention to society profile of osteosarcoma patients at dr. Soetomo General Hospital Surabaya “A retrospective study”. *Journal Orthopaedi and Traumatology Surabaya*, 7(1), pp.20-30, DOI: 10.20473/joints.v7i1.2018.20-30
- Ferrari, S. and Serra, M., 2015. An update on chemotherapy for osteosarcoma. *Expert opinion on pharmacotherapy*, 16(18), pp.2727-2736, DOI: 10.1517/14656566.2015.1102226
- Ferrari, S., Ruggieri, P., Cefalo, G., Tamburini, A., Capanna, R., Fagioli, F., Comandone, A., Bertulli, R., Bisogno, G., Palmerini, E. and Alberghini, M., 2012. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. *Journal of clinical oncology*, 30(17), pp.2112-2118, DOI: 10.1200/JCO.2011.38.4420
- Flarakos, C.C., Weiskopf, A., Robinson, M., Wang, G., Vouros, P., Sasso, G.J., Uskokovic, M.R. and Reddy, G.S., 2017. Metabolism of selective 20-epi-vitamin D3 analogs in rat osteosarcoma UMR-106 cells: isolation and identification of four novel C-1 fatty acid esters of 1 $\alpha$ , 25-dihydroxy-16-ene-20-epi-vitamin D3. *Steroids*, 119, pp.18-30, DOI: 10.1016/j.steroids.2016.12.013

- Friedman M.A., Carter SK et al., 2014. Review of Cancer Medicines on the WHO List of Essential Medicines.
- Fu, Y., Lan, T., Cai, H., Lu, A. and Yu, W., 2018. Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma. *Medicine*, 97(19), p.e0741.
- Gill, J. and Gorlick, R., 2021. Advancing therapy for osteosarcoma. *Nature reviews Clinical oncology*, 18(10), pp.609-624, DOI: 10.1038/s41571-021-00519-8
- Hanafy, E., Al Jabri, A., Gadelkarim, G., Dasaq, A., Nazim, F. and Al Pakrah, M., 2018. Tumor histopathological response to neoadjuvant chemotherapy in childhood solid malignancies: is it still impressive?. *Journal of Investigative Medicine*, 66(2), pp.289-297, DOI: 10.1136/jim-2017-000531
- Hricak, H., Husband, J. and Panicek, D.M., 2007. 'Guidelines for Radiologic Reporting of Common Cancers' in Hricak, H., Husband, J. and Panicek, D.M. (eds) *Oncologic Imaging: Essentials of Reporting Common Cancers*, Saunders, Philadelphia, pp. 2-13, DOI: 10.1016/b978-1-4160-3251-9.50005-4
- Huang, X., Zhao, J., Bai, J., Shen, H., Zhang, B., Deng, L., Sun, C., Liu, Y., Zhang, J. and Zheng, J., 2019. Risk and clinicopathological features of osteosarcoma metastasis to the lung: a population-based study. *Journal of bone oncology*, 16, p.100230, DOI: 10.1016/j.jbo.2019.100230
- Imbert-Bouteille, M., Gauthier-Villars, M., Leroux, D., Meunier, I., Aerts, I., Lumbroso-Le Rouic, L., Lejeune, S., Delnatte, C., Abadie, C., Pujol, P. and Houdayer, C., 2019. Osteosarcoma without prior retinoblastoma related to RB1 low-penetrance germline pathogenic variants: A novel type of RB1-related hereditary predisposition syndrome?. *Molecular genetics & genomic medicine*, 7(12), p.e913, DOI: 10.1002/mgg3.913
- Isakoff, M.S., Bielack, S.S., Meltzer, P. and Gorlick, R., 2015. Osteosarcoma: current treatment and a collaborative pathway to success. *Journal of clinical oncology*, 33(27), p.3029, DOI: 10.1200/JCO.2014.59.4895
- Jawad, M.U. and Scully, S.P., 2010. In brief: classifications in brief: enneking classification: benign and malignant tumors of the musculoskeletal system. *Clinical orthopaedics and related research*, 468(7), 2000–2002, DOI: 10.1007/s11999-010-1315-7
- Júnior, R.Z.B. and de Camargo, O.P., 2011. Is there any difference in the prognosis for patients with primary osteosarcoma with a poor response to neoadjuvant chemotherapy between huvos grades I and II?. *Revista Brasileira de Ortopedia (English Edition)*, 46(4), pp.420-423, DOI: 10.1016/S2255-4971(15)30256-1
- Komite Penanggulangan Kanker Nasional, 2018. *Panduan*

- Penatalaksanaan Osteosarkoma*. Kementerian Kesehatan Republik Indonesia, pp. 3-16, viewed 19 May 2024, (<http://202.70.136.213/guidelines/PPKOsteosarkoma.pdf>).
- Kundu, Z.S., 2014. Classification, imaging, biopsy and staging of osteosarcoma. *Indian journal of orthopaedics*, 48(3), pp.238-246, DOI: 10.4103/0019-5413.132491
- Lewis, I.J., Nooij, M.A., Whelan, J., Sydes, M.R., Grimer, R., Hogendoorn, P.C., Memon, M.A., Weeden, S., Uscinska, B.M., Van Glabbeke, M. and Kirkpatrick, A., 2007. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. *Journal of the National Cancer Institute*, 99(2), pp.112-128, DOI: 10.1093/jnci/djk015
- Li, G., Wang, Z., Xu, J., Wu, H., Cai, S. and He, Y., 2016. The prognostic value of lactate dehydrogenase levels in colorectal cancer: a meta-analysis. *BMC cancer*, 16, pp.1-9.
- Limmahakhun, S., Pothacharoen, P., Theera-Umpon, N., Arpornchayanon, O., Leerapun, T., Luevitoonvechkij, S. and Pruksakorn, D., 2011. Relationships between serum biomarker levels and clinical presentation of human osteosarcomas. *Asian Pac J Cancer Prev*, 12(7), pp.1717-22.
- Link, M.P., Goorin, A.M., Miser, A.W., Green, A.A., Pratt, C.B., Belasco, J.B., Pritchard, J., Malpas, J.S., Baker, A.R., Kirkpatrick, J.A. and Ayala, A.G., 1986. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. *New England Journal of Medicine*, 314(25), pp.1600-1606, DOI: 10.1056/NEJM198606193142502
- Marina, N.M., Smeland, S., Bielack, S.S., Bernstein, M., Jovic, G., Krailo, M.D., Hook, J.M., Arndt, C., van den Berg, H., Brennan, B. and Brichard, B., 2016. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. *The Lancet Oncology*, 17(10), pp.1396-1408, DOI: 10.1016/S1470-2045(16)30214-5
- Meyers, P.A., Schwartz, C.L., Krailo, M., Kleinerman, E.S., Betcher, D., Bernstein, M.L., Conrad, E., Ferguson, W., Gebhardt, M., Goorin, A.M. and Harris, M.B., 2005. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. *Journal of clinical oncology*, 23(9), pp.2004-2011, DOI: 10.1200/JCO.2005.06.031
- Meyers, P.A., Schwartz, C.L., Krailo, M.D., Healey, J.H., Bernstein, M.L., Betcher, D., Ferguson, W.S., Gebhardt, M.C., Goorin, A.M., Harris,

- M. and Kleinerman, E., 2008. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. *Journal of clinical oncology*, 26(4), pp.633-638, DOI: 10.1200/JCO.2008.14.0095
- Mirabello, L., Troisi, R.J. and Savage, S.A., 2009. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. *International journal of cancer*, 125(1), pp.229-234, DOI: 10.1002/ijc.24320
- Misaghi, A., Goldin, A., Awad, M. and Kulidjian, A.A., 2018. Osteosarcoma: a comprehensive review. *Sicot-j*, 4, DOI: 10.1051/sicotj/2017028
- Miwa, S., Takeuchi, A., Ikeda, H., Shirai, T., Yamamoto, N., Nishida, H., Hayashi, K., Tanzawa, Y., Kimura, H., Igarashi, K. and Tsuchiya, H., 2013. Prognostic value of histological response to chemotherapy in osteosarcoma patients receiving tumor-bearing frozen autograft. *PLoS One*, 8(8), p.e71362, DOI: 10.1371/journal.pone.0071362
- Ottaviani, G. and Jaffe, N., 2010. The epidemiology of osteosarcoma. *Pediatric and adolescent osteosarcoma*, pp.3-13, DOI: 10.1007/978-1-4419-0284-9\_1
- Parkin, D.M., Stiller, C.A., Draper, G.J. and Bieber, C.A., 1988. The international incidence of childhood cancer. *International Journal of Cancer*, 42(4), pp.511-520, DOI: 10.1002/ijc.2910420408
- Prabowo, Y., Setiawan, I., Kamal, A.F., Kodrat, E. and Labib Zufar, M.L., 2021. Correlation between prognostic factors and the histopathological response to neoadjuvant chemotherapy in osteosarcoma: a retrospective study. *International Journal of Surgical Oncology*, 2021(1), p.8843325, DOI: 10.1155/2021/8843325
- Prater, S. and McKeon, B., 2022. Osteosarcoma.[Updated 2021 Jun 4]. *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing.
- Provisor, A.J., Ettinger, L.J., Nachman, J.B., Krailo, M.D., Makley, J.T., Yunis, E.J., Huvos, A.G., Betcher, D.L., Baum, E.S., Kisker, C.T. and Miser, J.S., 1997. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. *Journal of Clinical Oncology*, 15(1), pp.76-84, DOI: 10.1200/JCO.1997.15.1.76
- Ritter, J. and Bielack, S.S., 2010. Osteosarcoma. *Annals of oncology*, 21, pp.vii320-vii325, DOI: 10.1093/annonc/mdq276.
- Robertson, J., Barr, R., Shulman, L.N., Forte, G.B. and Magrini, N., 2016. Essential medicines for cancer: WHO recommendations and national priorities. *Bulletin of the World Health Organization*, 94(10), p.735, DOI: 10.2471/BLT.15.163998
- Rosen, G., Caparros, B., Huvos, A.G., Kosloff, C., Nirenberg, A., Cacavio,

- A., Marcove, R.C., Lane, J.M., Mehta, B. and Urban, C., 1982. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. *Cancer*, 49(6), pp. 1221-1230, DOI: 10.1002/1097-0142(19820315)49:6<1221::aid-cncr2820490625>3.0.co;2-e
- Shen, J., Chen, Z., Zhuang, Q., Fan, M., Ding, T., Lu, H. and He, X., 2016. Prognostic value of serum lactate dehydrogenase in renal cell carcinoma: a systematic review and meta-analysis. *PLoS One*, 11(11), p.e0166482.
- Smeland, S., Bielack, S.S., Whelan, J., Bernstein, M., Hogendoorn, P., Krailo, M.D., Gorlick, R., Janeway, K.A., Ingleby, F.C., Anninga, J. and Antal, I., 2019. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. *European journal of cancer*, 109, pp.36-50, DOI: 10.1016/j.ejca.2018.11.027
- Smeland, S., Bruland, Ø.S., Hjorth, L., Brosjö, O., Bjerkehagen, B., Österlundh, G., Jakobson, Å., Hall, K.S., Monge, O.R., Björk, O. and Alvegaard, T.A., 2011. Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years. *Acta orthopaedica*, 82(2), pp.211-216, DOI: 10.3109/17453674.2011.566141
- Smrke, A., Anderson, P.M., Gulia, A., Gennatas, S., Huang, P.H. and Jones, R.L., 2021. Future directions in the treatment of osteosarcoma. *Cells*, 10(1), p.172, DOI: 10.3390/cel10010172.
- Souhami, R.L., Craft, A.W., Van der Eijken, J.W., Nooij, M., Spooner, D., Bramwell, V.H., Wierzbicki, R., Malcolm, A.J., Kirkpatrick, A., Uscinska, B.M. and Van Glabbeke, M., 1997. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. *The Lancet*, 350(9082), pp.911-917, DOI: 10.1016/S0140-6736(97)02307-6
- Thorn, C.F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T.E. and Altman, R.B., 2011. Doxorubicin pathways: pharmacodynamics and adverse effects. *Pharmacogenetics and genomics*, 21(7), pp.440-446, DOI: 10.1097/FPC.0b013e32833ffb56
- Verma, P., Jain, S., Kapoor, G., Tripathi, R., Sharma, P. and Doval, D.C., 2021. IAP chemotherapy regimen is a viable and cost-effective option in children and adolescents with osteosarcoma: a comparative analysis with MAP regimen on toxicity and survival. *Journal of Pediatric Hematology/Oncology*, 43(4), pp.e466-e471, DOI: 10.1097/MPH.0000000000001946
- Walenta, S. and Mueller-Klieser, W.F., 2004, July. Lactate: mirror and

motor of tumor malignancy. In *Seminars in radiation oncology* (Vol. 14, No. 3, pp. 267-274). WB Saunders.

- Whelan, J.S., Jinks, R.C., McTiernan, A., Sydes, M.R., Hook, J.M., Trani, L., Uscinska, B., Bramwell, V., Lewis, I.J., Nooij, M.A. and Van Glabbeke, M., 2012. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. *Annals of Oncology*, 23(6), pp.1607-1616, DOI: 10.1093/annonc/mdr491
- Yoshida, G.J., Fuchimoto, Y., Osumi, T., Shimada, H., Hosaka, S., Morioka, H., Mukai, M., Masugi, Y., Sakamoto, M. and Kuroda, T., 2012. Li-Fraumeni syndrome with simultaneous osteosarcoma and liver cancer: increased expression of a CD44 variant isoform after chemotherapy. *BMC cancer*, 12, pp. 444, DOI: 10.1186/1471-2407-12-444
- Zhang, X., Guo, M., Fan, J., Lv, Z., Huang, Q., Han, J., Wu, F., Hu, G., Xu, J. and Jin, Y., 2016. Prognostic significance of serum LDH in small cell lung cancer: a systematic review with meta-analysis. *Cancer Biomarkers*, 16(3), pp.415-423.
- Zhu, W., Zhu, L., Bao, Y., Zhong, X., Chen, Y. and Wu, Q., 2019. Clinical evaluation of neoadjuvant chemotherapy for osteosarcoma. *J buon*, 24(3), pp.1181-1185.
- Zumárraga, J.P., Baptista, A.M., Rosa, L.P.D.L., Caiero, M.T. and Camargo, O.P.D., 2016. Serum values of alkaline phosphatase and lactate dehydrogenase in osteosarcoma. *Acta Ortopedica Brasileira*, 24(3), pp.142-146, DOI: 10.1590/1413-785220162403157033